Log in
Login
Password
Remember
Lost password
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesHot NewsMost Read NewsRecomm.Business LeadersVideosCalendar 

Zogenix Inc. : Trading of Zogenix Common Stock Halted

12/07/2012 | 08:00am US/Eastern

FDA Advisory Committee Reviewing Zohydro™ ER New Drug Application

Zogenix to Host Conference Call at 6:30 pm ET Today

SAN DIEGO, Dec. 7, 2012 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, announced that NASDAQ halted trading of the company's common stock on December 7, 2012. The U.S. Food and Drug Administration's (FDA) Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) is meeting today to review the Company's New Drug Application (NDA) for Zohydro™ ER (hydrocodone bitartrate extended-release capsules).

Conference Call & Webcast

Zogenix will host a conference call to discuss the outcome of the AADPAC meeting today, Friday, December 7, 2012 at 6:30 p.m. ET (3:30 p.m. PT). To participate, please dial (800) 299-9086 (U.S.) or (617) 786-2903 (International); participant passcode: 21970283. To access the live webcast please visit the Zogenix Investor Relations website at http://ir.zogenix.com.  

The conference call will be hosted by Chief Executive Officer Roger L. Hawley and President and Chief Operating Officer Stephen J. Farr, Ph.D.

A replay of the conference call will be available beginning December 7, 2012 at 8:30 p.m. ET (5:30 p.m. PT) until December 14, 2012, by dialing (888) 286-8010 (U.S.) or (617) 801-6888 (International); passcode: 27116437. A replay of the webcast will also be accessible on the Investor Relations website for one month, through January 10, 2013.

About Anesthetic and Analgesic Drug Products Advisory Committee

The AADPAC reviews and evaluates available data concerning the safety and effectiveness of marketed and investigational human anesthetic and analgesic drug products and makes appropriate recommendations to the Commissioner of Food and Drugs. The AADPAC provides FDA with independent expert advice and recommendations, however, the final decision regarding approval is made by FDA.

About Zogenix

Zogenix, Inc., with offices in San Diego and Emeryville, California, is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. Zogenix's first commercial product, SUMAVEL® DosePro® (sumatriptan injection) Needle-free Delivery System, was launched in January 2010 for the acute treatment of migraine and cluster headache. Zogenix's lead investigational product candidate, ZohydroTM ER (hydrocodone bitartrate) is an oral, novel extended-release formulation of various strengths of hydrocodone without acetaminophen intended for administration every 12 hours for around the clock management of moderate to severe chronic pain. Zogenix's second DosePro investigational product candidate, ReldayTM, is a proprietary, long-acting injectable formulation of risperidone for the treatment of schizophrenia. In May 2012, Zogenix submitted to the FDA a New Drug Application for Zohydro ER and an Investigational New Drug Application for Relday. The FDA assigned a PDUFA target action date of March 1, 2013 for the Zohydro ER NDA.

For additional information, please visit www.zogenix.com.

SUMAVEL ®, DosePro ®, ReldayTM and ZohydroTM ER are trademarks of Zogenix, Inc.

CONTACT: INVESTORS:
         Zack Kubow | The Ruth Group
         646.536.7020 | zkubow@theruthgroup.com

         MEDIA:
         Emily Poe | WCG
         212.301.7183 | epoe@wcgworld.com
Zogenix
distributed by
React to this article
Latest news
Date Title
03:46p PAYPAL SEEN RISING 40 PERCENT FROM POST SPINOFF LOWS : Barron's
03:32p GAZIT GLOBE : invests NIS 125m to launch Yavne mall
03:32p Elbit Systems cyber security unit wins two contracts
03:32p OSEM INVESTMENT : BRIEF: Osem net profit down 10%
03:32p SANDISK : to hire 90 in Israel (BRIEF)
03:24p VISA : Universal Merchant Bank launches VISA card
03:17p REPUBLIC SERVICES : Cities will not file for rehearing in waste station case
03:17p EQUITY BANK : WAWERU: Africa needs a mix of venture capital and private equity funds
03:12p TRAFFIC TECHNOLOGIES : Msheireb awards car parking management system deal
03:11p ALDAR PROPERTIES PJSC : unit Khidmah wins 90 million riyal management contract for Saudi cultural centre
Latest news
Advertisement
Hot News 
OPPORTUNITY INVEST MGMT : 28 augustus 2015 - PRESS RELEASE: Announcement OIM 28 August 2015
MOLYCORP : Massive Mojave mine Molycorp to close, taking nearly 500 jobs
CHALLENGER ACQUISITIONS : Says It Is Focused On Integrating Starneth
MAVEN INCOME & GROWTH VCT : 4 Net Asset Value Total Return Rises
EUROCONSULT : 1,400 Satellites Projected to Launch Over Next Decade
Most Read News
08/29 NINTENDO NEWS : Xenoblade Chronicles X Special Edition Launches on Dec. 4
06:06a Volkswagen Launches Cultural Engagement Initiative in China With Opening of the Rain Room Exhibition in Shanghai
05:47a TWi Pharmaceuticals President & CEO Ms. Tina Guilder will resign from her current roles and Chairman Dr. Chih-Ming Chen will become interim President & CEO, leading the Company in its continued efforts to develop high-entry-barrier generics for the U.S. market
01:06a NIOC NATIONAL IRANIAN OIL : UKs Oil and Gas Giant Expresses Readiness to Return to Iran
01:05a Scott Dunn announce AED 3 million refurbishment of Chalet Eagle's Nest
Most recommended articles
03:46p PAYPAL SEEN RISING 40 PERCENT FROM POST SPINOFF LOWS : Barron's
03:08pDJBNY Mellon Races to Fix Pricing Glitches Before Markets Open Monday
02:21p BRITISH LAND : peer-to-peer lender Zopa appoints Janardana as CEO
12:50pDJKOCHERLAKOTA INTERVIEW TRANSCRIPT : Fed Shouldn't Tighten Policy Now
12:34p OSAMU SUZUKI : Suzuki Motor says it will buy back VW stake as court settles feud